Compare WDFC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WDFC | GLPG |
|---|---|---|
| Founded | 1953 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | N/A | 2005 |
| Metric | WDFC | GLPG |
|---|---|---|
| Price | $225.43 | $34.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $300.00 | $31.33 |
| AVG Volume (30 Days) | ★ 208.9K | 122.2K |
| Earning Date | 01-08-2026 | 02-23-2026 |
| Dividend Yield | ★ 1.81% | N/A |
| EPS Growth | ★ 26.07 | N/A |
| EPS | ★ 6.58 | N/A |
| Revenue | ★ $620,913,000.00 | $336,643,201.00 |
| Revenue This Year | $7.09 | $1.76 |
| Revenue Next Year | $6.02 | $0.49 |
| P/E Ratio | $34.32 | ★ N/A |
| Revenue Growth | 2.86 | ★ 10.31 |
| 52 Week Low | $175.38 | $22.36 |
| 52 Week High | $253.48 | $37.78 |
| Indicator | WDFC | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 75.11 | 61.40 |
| Support Level | $199.43 | $34.18 |
| Resistance Level | $206.90 | $35.06 |
| Average True Range (ATR) | 6.85 | 0.66 |
| MACD | 2.21 | 0.03 |
| Stochastic Oscillator | 100.00 | 71.67 |
WD-40 Co is a global marketing organization focused on developing and selling products that solve maintenance and cleaning problems internationally. It offers two product groups: maintenance products, including the flagship WD-40 Multi-Use Product, which serves as a lubricant, rust preventative, penetrant, and moisture displacer, marketed globally; and homecare and cleaning products, mainly sold in North America, the UK, and Australia. The company distributes its products through hardware stores, automotive parts outlets, industrial suppliers, mass retailers, online platforms, and specialty retailers across the Americas, EIMEA, and Asia-Pacific, with the majority of revenue generated in the Americas.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.